The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition.
The FDA has historically regarded insulin as... Read more »
Since a major restructuring at Five Prime Therapeutics in October that kicked off a wind-down of most of its research and preclinical efforts, the company has been looking to add to its partnerships portfolio.
On Wednesday, South San Francisco-based Five Prime... Read more »
Spruce Biosciences has raised $88 million to advance clinical testing of a drug for a rare inherited endocrine disorder that can lead to a potentially life-threatening hormonal imbalance.
San Francisco-based Spruce aims to treat a form of congenital adrenal hyperplasia (CAH),... Read more »
Many companies are working to develop new drugs that target harmful proteins associated with neurodegenerative diseases.
EnClear Therapies has raised a $10 million Series A round of financing from a syndicate of investors to advance a device that it says could... Read more »
A Teva Pharmaceutical drug in testing as a treatment for tics in pediatric patients with moderate-to-severe Tourette syndrome has failed two late-stage trials.
Israel-based Teva (NYSE: TEVA) said Wednesday that the drug, deutetrabenazine, didn’t beat a placebo in reducing motor... Read more »
Join Xconomy on April 29 at Takeda Pharmaceuticals’ Boston location for the next in our Xcelerating Life Sciences event series: Biopharma’s Future in Digital Health. The half-day conference will bring together innovators, executives, rising pioneers, entrepreneurs, investors, and scientists to... Read more »
Three months after resTORbio’s lead drug failed a pivotal test treating lung infections in the elderly, the company is now looking for someone to buy the firm or strike a deal for its technology.
In a corporate update issued Wednesday,... Read more »
A year ago Five Prime Therapeutics cut a fifth of its workforce to save money as its worked to advance its clinical-stage drugs for solid tumor cancers.
On Tuesday the company (NASDAQ: FPRX) said one of those drugs, cabiralizumab, a... Read more »
Sickle cell disease research is seeing a flurry of activity with several companies currently testing therapies for the genetic blood disorder and one company recently receiving FDA approval. Imara aims set itself apart from the pack and it is preparing to... Read more »
CNS and cancer will be biopharma battlegrounds this year according to Philadelphia-based Clarivate Analytics, which says new medicines will reshape the US market.
The US Food and Drug Administration (FDA) looks set to approve several innovative therapies for central nervous system... Read more »
A contraceptive patch developed by Agile Therapeutics was awarded FDA approval late Friday, clearing the way for a new birth control option to reach the market.
The Agile (NASDAQ: AGRX) product, called Twirla, deliver delivers a combination of hormones via... Read more »
Drugs typically go through three phases of clinical testing to support an application for FDA approval. It’s easy to overlook Phase 4, which takes place after a drug reaches the market.
Post-marketing studies aim to identify side effects not observed in... Read more »
Eisai is withdrawing weight-loss drug lorcaserin after a post-marketing study found a higher incidence of cancer in patients who took the medicine.
The FDA said Thursday that its request for removal of the product from the market is voluntary, but Eisai... Read more »